More on VERU

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+40.0% Growth)
- Ratings (8.9 Score)

Upcoming Events

- Earnings (12/1/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Veru, Inc. (NQ:VERU)
Delayed: 2.61 +0.02 (0.77%)
Prev. Close $2.59  
Open$2.60 
52 Wk High$ 
52 Wk Low$ 
Day High$2.64 
Day Low$2.59 
P/E N/A  
EPS$ 
Volume84,381 


Aug 17, 2026 04:26 PM Form 4 VERU INC. For: Aug 13 Filed by: BARNETTE K GARY
Aug 10, 2026 08:52 AM Form 10-Q VERU INC. For: Jun 30
Aug 10, 2026 08:13 AM Veru, Inc. (VERU) Tops Q3 EPS by 1c
Aug 10, 2026 07:00 AM Form 8-K VERU INC. For: Aug 10
Aug 10, 2026 06:30 AM Veru posts Q3 loss, reports full enrollment in obesity drug trial
Aug 10, 2026 06:30 AM Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aug 4, 2026 08:30 AM Veru receives patent allowance for enobosarm and semaglutide combo
Aug 4, 2026 08:30 AM Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Aug 3, 2026 08:30 AM Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Jul 30, 2026 08:30 AM Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
View All Articles

Entities mentioned with VERU

View All Entities